Vaccines Companies
Largest dedicated vaccines P&L among the European names. FY 2025 vaccines £9.157B (+2% CER): Shingrix £3.558B, meningitis £1.583B, Arexvy £593M. Ex-US is now 66% of Shingrix.
Vaccine Milestones
Glaxo Wellcome and SmithKline Beecham complete the merger that creates GlaxoSmithKline (27 Dec 2000). The vaccines P&L (Rixensart, Belgium) is inside this combination.
FDA licenses Shingrix on 20 Oct 2017 for adults 50+. AS01 adjuvanted recombinant zoster. This becomes GSK's largest vaccine and 66% ex-US by 2025.
FDA approves Arexvy, first adult RSV vaccine. Wall Street priced an annual franchise. ACIP later refused that frame.
ACIP RSV: all adults 75+, risk-based 60-74, not annual. Arexvy falls from £1.238B (2023) toward ~£0.6B.
FY 2025 vaccines £9.157B. Shingrix £3.558B with 66% ex-US as US immunization hits 44%. Meningitis £1.583B. Arexvy £593M.
